Literature DB >> 4053414

The effect of spironolactone on hirsutism and female androgen metabolism.

P Dorrington-Ward, A C McCartney, S Holland, J Scully, G Carter, J Alaghband-Zadeh, P Wise.   

Abstract

An objective evaluation of the anti-androgen effects of spironolactone was performed in a consecutive series of 12 hirsute patients receiving a daily dose of 150 mg; nine completed the study. Using a computer assisted image analyser, hair diameter on two weekly shavings decreased significantly over a 12 month period in three of the patients, although growth rate and mean diameter did not change in the group as a whole. Plasma testosterone fell significantly to a mean of 53% of basal levels. The mean free testosterone (derived) fell significantly to 64% of basal by the sixth month (P = less than 0.005) and remained significantly depressed the remainder of the study. There was subjective benefit in hair growth and greasiness and a significant reduction in the semi-objective Ferriman-Gallwey index in nine of 10 subjects assessed for at least 9 months. We conclude that although spironolactone was not consistently successful, it may represent effective therapy for a sub group of patients with hirsutism.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4053414     DOI: 10.1111/j.1365-2265.1985.tb00211.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

Review 1.  How actual is the treatment with antiandrogen alone in patients with polycystic ovary syndrome?

Authors:  E Diamanti-Kandarakis
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 2.  Hirsutism and the effectiveness of spironolactone in its management.

Authors:  G R McMullen; A J Van Herle
Journal:  J Endocrinol Invest       Date:  1993-12       Impact factor: 4.256

Review 3.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

4.  Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.

Authors:  D J Evans; C W Burke
Journal:  J R Soc Med       Date:  1986-08       Impact factor: 5.344

Review 5.  Alopecia and hirsuties. Current concepts in pathogenesis and management.

Authors:  J H Barth
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

6.  Lack of endocrine systemic side effects after topical application of spironolactone in man.

Authors:  F O Rey; C Valterio; L Locatelli; A A Ramelet; J P Felber
Journal:  J Endocrinol Invest       Date:  1988-04       Impact factor: 4.256

7.  Endocrine and clinical effects of spironolactone in female hyperandrogenism.

Authors:  R Siegberg; P Ylöstalo; T Laatikainen; R Pelkonen; U H Stenman
Journal:  Arch Gynecol       Date:  1987

8.  Lack of effect of spironolactone on hair shaft diameter in hirsute females.

Authors:  A R McLellan; J Rentoul; R MacKie; G T McInnes
Journal:  Postgrad Med J       Date:  1989-07       Impact factor: 2.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.